Phase 2 N=105 Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=69 Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Clinical Response Rate — 17 Percentage of participants
Phase 3 N=925 A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
Non-Small Cell Lung Cancer (NSCLC)
Primary: Arm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR) — 16.69; 15.64 months — p=0.6460
Phase 3 N=453 A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 10.3; 9.2 Months — p=0.025
Phase 3 N=598 Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
Phase 2 N=39 Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 8.5 months
Phase 2 N=137 A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) — 32; 21; 23 percentage of participants
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Phase 2 N=84 A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Proportion of Subjects Surviving at One Year — 0.405 proportion
Phase 3 N=904 A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung
Primary: Overall Survival (OS) in the ITT (Non-squamous) Population — 376; 379 days — p=0.401
Phase 2 N=37 BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Phase 2 N=90 A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 1 Year Progression Free Survival — 53.7 percentage of participants — p=0.0645
Phase 2 N=117 Navelbine And Radiotherapy in Locally Advanced Lung Cancer
Non-small Cell Lung Cancer
Primary: Local Failure Free Survival — 9.4; 9.9 months
Phase 3 N=939 Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 2.89; 2.76; 2.37; 1.54 months — p=0.756
Phase 3 N=260 Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Survival Without Grade 3 or 4 Toxicity — 3.2; 0.7 months — p=<0.001
Phase 2 N=811 An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
Non-Small Cell Lung Cancer
Primary: Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events — 1; 7; 0; 1 Participants
Phase 2 N=71 Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas…
Phase 2 N=9 Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
Lung Cancer
Primary: Objective Response Rate (ORR), Presented in Numbers of Participants — 0; 0; 1; 1 Participants
Phase 2 N=46 Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients
Non Small Cell Lung Cancer
Primary: Progression Free Survival — 77.1 percentage of participants
Phase 2 N=32 Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Phase 2 N=28 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Phase 2 N=133 Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)
Non-Small-Cell Lung Cancer
Primary: Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate) — 52.8; 39.3 percentage
Phase 2 N=27 Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)
Lung Cancer
Primary: Median Progression Free Survival (PFS) — 7.5 months
Phase 2 N=82 Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 29; 50 percentage of participants
Phase 2 N=103 ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer
Advanced Non-small Cell Lung Cancer (NSCLC)
Primary: Response Rate (Centrally Assessed) — 13.6; 19.6 percentage of participants
Phase 2 N=341 A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS), Groups A-D Only — 15.0; 6.7; 6.0; 5.9 Months — p=0.5050
Phase 3 N=357 Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
Squamous NSCLC
Primary: PFS(Progression Free Survival) — 5.5; 4.9 months
Phase 2 N=166 Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Overall Objective Response Rate (ORR) — 8.1; 10.9 percentage of participants
N/A N=996 Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Adverse Drug Reactions (ADRs), Toxicities, Avastin-Related ADRs, and Serious ADRs — 88.6; 88.2; 27.0; 11.1 percentage of participants
Phase 2 N=46 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants